title: [Catalytic autoantibodies as a new molecular instrument in rheumatological practice].
abstract: OBJECTIVE
  To compare clinicopathogenetic value of DNA-hydrolizing autoantibodies or DNA-abzymes in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
  
  
  METHODS
  We studied sera from 180 patients with SLE, 180 RA patients and 128 healthy donors matched by age and gender; assessed catalytic and cytotoxic activity of DNA-abzymes in patients with different variants of SLE and RA course.
  
  
  RESULTS
  The highest catalytic and cytotoxic activities of DNA abzymes were observed in SLE patients. In SLE catalytic and cytotoxic activities of DNA abzymes ranged widely and their mean values depended on SLE activity in patients with systemic lesions. DNA-abzymes in RA patients showed lower catalytic and cytotoxic activities in relation to substrate DNA and target cells than in SLE. DNA-abzymes occurred most frequently in patients with high activity of RA, slow-progressive and lingering course of RA, especially in early development of visceral (extra-articular) pathology. Characteristic for DNA-abzymes in RA and SLE is the phenomenon of wide-range fluctuations due to factors determinating probability of induction of function of Ab-mediated catalysis and, therefore, incidence rates of DNA-abzymes, probably catalytic autoAb of the other specificity in a population of patients with systemic autoimmune diseases.
  
  
  CONCLUSIONS
  The data indicate the validity of DNA abzymes use in clinical practice for realization of diagnostic and therapeutic programs in SLE and RA.
authors.forename: A N
authors.initials: AN
authors.lastname: Khitrov
authors.forename: K A
authors.initials: KA
authors.lastname: Mal'tsev
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Vvedenskaia
authors.forename: N A
authors.initials: NA
authors.lastname: Ponomarenko
authors.forename: M A
authors.initials: MA
authors.lastname: Isaeva
authors.forename: M V
authors.initials: MV
authors.lastname: Kimova
authors.forename: E B
authors.initials: EB
authors.lastname: Tret'iak
authors.forename: Z S
authors.initials: ZS
authors.lastname: Shogenov
authors.forename: Z S
authors.initials: ZS
authors.lastname: Alekberova
authors.forename: A G
authors.initials: AG
authors.lastname: Gabibov
authors.forename: S V
authors.initials: SV
authors.lastname: Suchkov
mesh_terms: D000328:Adult; D000368:Aged; D017151:Antibodies, Catalytic / Q000235:genetics / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000235:genetics* / Q000276:immunology*; D001323:Autoantibodies / Q000235:genetics / Q000276:immunology*; D021881:DNA, Catalytic / Q000235:genetics*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000235:genetics* / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D017151:Antibodies, Catalytic; D001323:Autoantibodies; D021881:DNA, Catalytic; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M